Research press release


Nature Medicine

Bacteria transplants mitigate colitis from cancer immunotherapy



Y Wangたちは、免疫療法を受けた後に大腸炎を発症した2人のがん患者に、健康なドナーの糞便中微生物相を移植した。移植後に患者の大腸炎の症状は軽減し、移植の前後に患者から採取した糞便試料を調べたところ、腸を保護するように働く細菌群が移植によって腸内マイクロバイオーム中に復活し、大腸炎に伴う炎症が消散したことが分かった。


Severe colitis resulting from immunotherapy has been treated in two cancer patients by transplanting gut bacteria from healthy donors, reports a study published online this week in Nature Medicine.

Immunotherapy has revolutionized cancer treatment. Yet, despite its success, it is frequently accompanied by severe immune-related toxicities that are detrimental for patients and often lead to treatment discontinuation. One such side effect is severe colitis, the inflammation of the inner lining of the colon, which has been associated with alterations to the gut microbiome in immunotherapy patients.

Yinghong Wang and colleagues transplanted fecal microbiota from healthy donors into two cancer patients who had developed colitis following immunotherapy. Following the transplant, the patients’ colitis symptoms abated. The authors collected stool samples from the patients before and after the procedure and found that the transplant restored protective bacteria to the gut microbiome and resolved the inflammation associated with colitis.

Although these findings need to be confirmed in larger patient populations and a clinical trial setting, the authors demonstrate the potential of fecal transplants in treating a major adverse side effect of cancer immunotherapy.

doi: 10.1038/s41591-018-0238-9


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。